Tumor cell destruction

"Tumor cell destruction" refers to the biological and therapeutic process of inducing death in malignant cells, serving as the primary objective of oncological interventions. It is not a specific molecular target, such as a receptor or enzyme, but rather a complex physiological endpoint achieved through various pathways including apoptosis, necrosis, ferroptosis, and immunogenic cell death [1][2]. Therapeutic modalities such as cytotoxic chemotherapy and radiotherapy induce destruction by causing irreparable DNA damage or mitotic catastrophe, while targeted therapies inhibit specific signaling nodes required for cell survival [3]. Modern immunotherapies, including checkpoint inhibitors and CAR-T cell therapies, facilitate tumor cell destruction by activating the host immune system to recognize and lyse cancerous cells [4]. Monitoring the efficacy of this process often involves clinical imaging and the measurement of biomarkers like circulating tumor DNA (ctDNA) or intracellular enzymes released during lysis [5]. However, rapid or widespread tumor cell destruction can lead to clinical complications such as tumor lysis syndrome, which requires careful medical management [6]. Sources: [1] NIH National Cancer Institute, "Cell Death," NCI Dictionary of Cancer Terms. [2] PubMed: Galluzzi et al., "Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018," Cell Death & Differentiation. [3] StatPearls, "Physiology, Apoptosis." [4] NIH National Cancer Institute, "Immunotherapy to Treat Cancer." [5] PubMed: Diehl et al., "Circulating tumor DNA to monitor metastatic tumor burden." [6] StatPearls, "Tumor Lysis Syndrome."

Other names

CytolysisOncolysisTumor cell killingAntitumor activityCancer cell death

Induction of programmed cell death (apoptosis), direct cytotoxic necrosis, or immune-mediated lysis through T-cell or NK-cell activation.